SubHero Banner

Dupixent® (dupilumab) – Expanded indication

March 11, 2019 - Regeneron Pharmaceuticals and Sanofi announced the FDA approval of Dupixent (dupilumab), for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

Download PDF